Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Background. Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). Dose reductions are commonly performed due to decreased tolerability and adverse effects. This retrospective multicenter study analyzed overall survival (OS) and progression-free survival (...

Full description

Saved in:
Bibliographic Details
Main Authors: G. Rendl, B. Sipos, A. Becherer, S. Sorko, C. Trummer, M. Raderer, W. Hitzl, M. Ardelt, H. J. Gallowitsch, C. Pirich
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2020/8834148
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items